UNICEF and Gavi ask industry on plans for COVID-19 vaccine production
The two organizations have published an Expression of Interest (EOI) to gather information on the production potential of a coronavirus vaccine.
With the EOI, UNICEF and Gavi, the Vaccine Alliance (Gavi), expect to collect information from manufacturers and developers on their plans to deliver COVID-19 vaccines to protect against the SARS-CoV-2 virus. The information will help in the design of the procurement, budgeting and timelines of the COVID-19 Vaccine Global Access (COVAX) Facility and Gavi COVAX Advance Market Commitment (AMC).
Feedback will contribute to understanding the potential availability and commercialization issues of the COVID-19 vaccine. The information will also help UNICEF, Gavi and other stakeholders understand the support that developers and manufacturers need to bring their COVID-19 vaccines to market.
UNICEF and Gavi expect to initiate procurement of COVID-19 vaccines in 2020 or whenever one or more vaccine candidates demonstrate efficacy and safety. Developers and manufacturers are therefore urged to provide a response to this request if they are currently developing or producing a COVID-19 vaccine and consider likely that they would offer the product to the ACT Accelerator COVAX Facility.
The information received through this EOI will be treated as confidential. Significant findings will be summarised and shared with key partners of the ACT Accelerator.
This document is a request for an EOI and sharing of information only and the indications made by each developer or manufacturer will not be considered by UNICEF or Gavi in any way binding.
The EOI is available on the United Nations Global Market (UNGM) website and the responses must be sent by 22 June 2020, at 12:00 p.m. Copenhagen time.
